Hassan Fred — SEC insider filings
SEC reporting owner CIK 1110744. 33 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2021-03-16 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 589,645 shares, $1,271,494 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 55.
- Largest priced transaction: purchase of 570,345 shares @ $1.75 ($998,104) in PRECIGEN, INC., filed 2023-08-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PRECIGEN, INC. (PGEN) | Director | 12 | 1 leg · 570,345 sh · $998,104 | — | 30 |
| BridgeBio Pharma, Inc. (BBIO) | Director | 7 | 1 leg · 19,300 sh · $273,390 | — | 8 |
| Prometheus Biosciences, Inc. (RXDX) | Director | 5 | — | — | 8 |
| Cocrystal Pharma, Inc. (COCP) | Director | 4 | — | — | 5 |
| EyePoint, Inc. (EYPT) | Director | 3 | — | — | 3 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | 2 | — | — | 1 |
Insider filings — Hassan Fred
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 3 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Holdings only — no transactions reported | EDGAR |
| 2026-11-04 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 156,658 @ $0 | EDGAR |
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 71,839 · Option exercise (M): 71,839 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 17,948 @ $3.51 · Grant/award (A): 35,612 (derivative) @ $0 · Grant/award (A): 41,073 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 16,410 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | EyePoint, Inc. (EYPT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 359,713 @ $1.39 · Grant/award (A): 719,426 (derivative) @ $1.39 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 36,206 @ $1.74 · Option exercise (M): 87,412 · Grant/award (A): 71,839 (derivative) @ $0 · Option exercise (M): 87,412 (derivative) @ $0 · Grant/award (A): 83,517 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-10-11 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 8,067 | EDGAR |
| 2024-09-05 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 44,055 @ $1.43 · Grant/award (A): 87,412 (derivative) @ $0 · Grant/award (A): 101,626 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 106,837 · Option exercise (M): 106,837 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | PRECIGEN, INC. (PGEN) | Purchase (P): 570,345 @ $1.75 | EDGAR |
| 2023-07-20 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 7,333 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 51,501 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Disposition to issuer (D): 2,123 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 541 (derivative) · Disposition to issuer (D): 21,013 (derivative) | EDGAR |
| 2023-05-19 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 2,123 @ $0 | EDGAR |
| 2023-03-13 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 48,290 @ $1.17 · Grant/award (A): 106,837 (derivative) @ $0 · Grant/award (A): 125,489 (derivative) @ $0 | EDGAR |
| 2023-02-24 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 61,576 · Option exercise (M): 61,576 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 104,921 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 21,013 (derivative) @ $0 | EDGAR |
| 2022-03-29 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 16,212 · Option exercise (M): 16,212 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 27,832 @ $2.03 · Grant/award (A): 61,576 (derivative) @ $0 · Grant/award (A): 83,189 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | BridgeBio Pharma, Inc. (BBIO) | Purchase (P): 19,300 @ $14.17 | EDGAR |
| 2021-11-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 541 (derivative) @ $0 | EDGAR |
| 2021-08-26 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 49,869 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-03-29 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 7,328 @ $7.71 · Grant/award (A): 16,212 (derivative) @ $0 · Grant/award (A): 22,107 (derivative) @ $0 | EDGAR |
| 2021-03-16 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 62,189 · Option exercise (M): 62,189 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1110744 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs